Loading
Mariana Oncology
Mariana Oncology designs small protein fragments that carry a radioactive isotope to tumours, starting with small cell lung cancer. Novartis bought the company in 2024 for 1 billion dollars up front.
Overview
Mariana Oncology, founded in 2021 in Watertown, Massachusetts by Atlas Venture, Access Biotechnology and RA Capital Management, built a fully integrated radiopharmaceutical platform combining peptide discovery, radiochemistry, in-house GMP manufacturing, isotope supply and formulations to extend product shelf life. Its portfolio of peptide-based radioligand therapies addresses a range of solid tumours; the lead candidate MC-339 is a radioligand therapy for small cell lung cancer that was expected to enter the clinic in 2024. The company closed a USD 175 million Series B in September 2023 co-led by Deep Track Capital and Forbion, and in May 2024 agreed to be acquired by Novartis for USD 1 billion upfront and up to USD 750 million in milestones. As a Novartis company it announced a USD 50 million expansion of radioligand R&D facilities in June 2025.
Headquarters
Watertown, MA, US
Funding
All startupsAcquiredAcquired by Novartis
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · USD 1 billion upfront plus up to USD 750 million in milestones | 2024 | $1B | marianaoncology.com |
| Series B | 2023 | $175M | marianaoncology.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Acquired
Website
Founded
2021
Notes
- MC-339 target not stated on fetched pages. Series A not fetched and omitted.
Connected
7Similar pages
- CompanySolstice Oncology
Shares Forbion, RA Capital Management.
- CompanyPheon Therapeutics
Shares Forbion, Atlas Venture.
- CompanyAriceum Therapeutics
Shares Radioligand therapy (beta emitters), Small-cell lung cancer.
- TrialStudy to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
- CompanyObsidian Therapeutics
Shares Atlas Venture, RA Capital Management.
- CompanyTriana Biomedicines
Shares Atlas Venture, RA Capital Management.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
marianaoncology.com · 3
A source that has moved or gone is reported by the weekly link check. /audit/